Each journal will select 1–2 EITs through an independent search. Ideal candidates are early-career scientists (within the ...
Aficamten, omecamtiv mecarbil, ulacamten and CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA ...
Equitable R&D funding is key to unleashing HBCUs’ wellspring of innovation to improve America’s health, economic growth, and ...
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for Enhertu plus pertuzumab has been accepted for Priority Review b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results